Monolaurin (Lauric Acid Derivative).
From coconut. Disrupts lipid envelopes of viruses and bacteria. Antimicrobial. Dissolves lipid envelopes of viruses and bacteria.
Reviewed March 2026
- Category
- Compound
- Also filed under
- AntiviralAntibacterialEnvelope disruption
What Monolaurin (Lauric Acid Derivative) is, and what it does.
- Does it work
- Moderate. Strong lab data. Clinical trials catching up.
- How much to take
- Start with 600mg a day and work up toward 1,800mg. That's the band a daily habit runs on. The 3,000mg used in research is a study condition, not a daily target.
- Time to feel it
- Taken daily, this runs in the background. There's no measured onset in people, so nobody can hand you a week-by-week curve yet.
- The first dose
- Day one is usually uneventful. Some people notice mild digestive rumbling when they start near the top of the band, which is why building up gradually suits most people.
- With regular use
- Variable. Acute issues faster. Chronic issues need months.
- How well tolerated
- Start low. Die-off reactions possible. Generally well tolerated.
- How it feels
- Usually nothing. Herx reactions if killing off infections.
- The overlooked benefit
- Chain length decides the route, not the label. The twelve-carbon fat it releases travels largely by the portal vein rather than the lymphatic path long-chain fats take.
600 to 1,800mg a day is where Monolaurin (Lauric Acid Derivative) works.
Source: Preuss et al., J Med Food, 2005; in vitro antimicrobial data
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Monolaurin (Lauric Acid Derivative) has emerging evidence. Based on 765+ studies.
- Activity against lipid-enveloped organisms in cultureIn vitro study
- Insertion into and permeabilisation of lipid bilayersIn vitro study
- Portal transport of medium-chain fatty acids released in the gutNarrative review
- Emulsifier function in oil and water mixturesNarrative review
- Immune cell signalling responsesAnimal study
Questions people ask about Monolaurin (Lauric Acid Derivative).
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- People who've already covered the basics (diet, sleep, exercise) and want to fine-tune. It's not essential, but could be worthwhile for the right person.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Monolaurin and caprylic acid are both amphipathic medium chain lipids that insert into and destabilise lipid bilayers, which is why they appear together in the same formulas. They partition into membranes of different composition.
Monolaurin is the monoglyceride of lauric acid, a C12 chain from the same coconut fraction that yields MCT oil, and it is poorly water dispersible on its own. A medium chain lipid vehicle keeps it in a lipid phase through the upper gut.
Carvacrol from oregano and monolaurin both act at the lipid membrane but by different routes, one as a small phenol that raises permeability and one as a monoglyceride that disorders the bilayer. They are combined in practice for that complementarity.
Lactoferrin works by sequestering free iron and by binding bacterial surface structures, which is separate from the membrane-partitioning action of monolaurin. Formulas pair them so the two arms do not overlap.
Oleuropein and its hydrolysis product hydroxytyrosol act as phenolic membrane-permeabilising agents, a different chemistry from a monoglyceride. The combination is common formulation practice in microbial balance blends.
Pancreatic lipase and intestinal esterases cleave monoacylglycerols to free fatty acid and glycerol. Added lipase in a digestive enzyme blend acts on the same bond, so it shifts the ratio of intact monoglyceride to free lauric acid reaching the lower gut. Whether that matters depends on which of the two forms a formula is aiming at.
Monolaurin is a solid at room temperature and disperses poorly in water. Lecithin phospholipids lower interfacial tension and hold it in a dispersed state, which is why lecithin appears in liquid and softgel presentations. This is formulation chemistry rather than a physiological interaction.
Phosphatidylcholine forms mixed micelles with monoacylglycerols during normal fat digestion, the same physical process that carries dietary lipid across the enterocyte membrane. In a formula it serves as a dispersing vehicle. The chemistry is settled; the effect on how much intact monolaurin survives digestion has not been measured in people.
Tocopherols are the conventional chain-breaking antioxidant in oil-based and lipid-pellet products. They protect the carrier oil more than the saturated monoglyceride itself, since a saturated C12 chain has no double bonds to oxidise. The pairing is about shelf chemistry, not about a shared action in the body.
Caprylic acid triglyceride is liquid at room temperature and dissolves monolaurin readily, which makes it the usual carrier in liquid presentations. Both are medium-chain lipids that reach the portal circulation more directly than long-chain fats. Read the pairing as delivery chemistry plus a shared class, not as a combination with a measured joint outcome.
Monolaurin disrupts lipid membranes without selecting between organisms, and laboratory work on monoglycerides shows activity across gram-positive bacteria. Supplemented lactobacilli are gram-positive. Spacing the two doses is common formulation practice; the interaction is demonstrated in vitro and its size in a human gut is unmeasured.
S. boulardii is a yeast with a chitin and glucan wall rather than a bacterial phospholipid bilayer of the kind monoglyceride surfactants act on most readily. That structural difference is the reason the yeast probiotic is the one usually paired with antimicrobial lipids. The reasoning is microbiological, and no combination trial in people is available.
Yeast beta-glucan is recognised by dectin-1 on innate immune cells, a receptor pathway with nothing to do with membrane-active lipids. Formulators combine them because the two routes are independent rather than overlapping. Each has its own literature; the pair does not.
Calcitriol acts through the vitamin D receptor on monocytes and lymphocytes and supports the normal expression of endogenous antimicrobial peptides. That is a transcriptional route and monolaurin is a physical membrane agent, so the two contribute to normal immune function by wholly separate means. The vitamin D receptor biology is settled; the pairing has not been studied as a pair.
Zinc is structural in hundreds of enzymes and transcription factors, including those governing lymphocyte development. Its role in normal immune competence is textbook nutrition. Combining it with a membrane-active lipid pairs a nutrient requirement with a physical mechanism, which is why immune formulas carry both.
Bovine colostrum contributes IgG and glycoproteins that act in the gut lumen, an entirely different mode from a surfactant lipid. The two are combined in gut-directed formulas on that complementary logic. Human data on the combination is not available.
Aged garlic contributes S-allyl cysteine and related organosulfur compounds, which act through thiol chemistry rather than membrane disruption. Blends pair them for that non-overlap. The rationale is mechanistic and the pair has no clinical study behind it.
Berberine is a quaternary isoquinoline alkaloid with poor oral bioavailability, so much of a dose acts in the gut lumen. Monolaurin also acts substantially in the lumen but by physical membrane interaction. Two different routes in the same compartment is the formulation argument; no combination data exists.
Propolis carries galangin, pinocembrin and caffeic acid esters, all polyphenols rather than lipids. Traditional immune blends combine the two categories. This one is thin: traditional use plus separate laboratory work on each, not a study of the pair.
Nothing specific on file for Monolaurin (Lauric Acid Derivative). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Monolaurin (Lauric Acid Derivative) actually does.
Monolaurin is glycerol monolaurate, the monoester of the twelve-carbon saturated fatty acid lauric acid with glycerol. The molecule is amphiphilic: a polar glycerol head with two free hydroxyls and a single saturated tail, which is what lets it insert into lipid bilayers.
Normal fat digestion produces monoacylglycerols from dietary triglyceride through pancreatic lipase acting at the sn-1 and sn-3 positions. Monolaurin taken orally therefore enters an existing metabolic route rather than a novel one, and intestinal esterases can hydrolyse it back to lauric acid and glycerol.
Medium-chain fatty acids released in the gut are absorbed and carried largely by the portal vein bound to albumin, bypassing the chylomicron and lymphatic route that long-chain fats take. Chain length, not the supplement label, decides which route applies.
Coconut and palm kernel oils are the practical lauric acid feedstocks because roughly half of their fatty acid content is C12, which is unusual among common food fats.
Where Monolaurin (Lauric Acid Derivative) comes from.
Coconut oil is split into its fatty acids, the twelve-carbon one is separated out, and it is joined back onto glycerol either with heat and a catalyst or with an enzyme. A vacuum distillation step cleans up the leftovers, and the batch is tested for how much of the single-tailed molecule it actually contains.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
Both are unusually rich in the twelve-carbon fatty acid, roughly half their fatty acid content, which is why they are the commercial starting point.
The triglyceride is split by high-pressure steam hydrolysis into free fatty acids and glycerol, then fractionally distilled to separate the C12 cut from shorter and longer chains.
Lauric acid is reacted with glycerol. The route may be chemical, using an alkaline catalyst at elevated temperature, or enzymatic, using an immobilised lipase at lower temperature. Chemical esterification runs faster and gives a broader mix of mono-, di- and triester; the enzymatic route runs milder and more selectively for the monoester and costs more per kilogram.
Short-path distillation under high vacuum removes unreacted acid, glycerol and most of the diester, raising monoester content toward 90 percent or higher.
Batches are assayed by gas chromatography for monoester content and free glycerol. The declared figure is monoester percentage.
Molten material is prilled into pellets, dissolved into an MCT carrier, or co-processed with lecithin for dispersible powders.
Getting Monolaurin (Lauric Acid Derivative) from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- A medium-chain triglyceride emulsion containing phytocannabinoids and monolaurin was reported to improve growth and survival in suckling piglets, and the design cannot separate the monolaurin contribution from the rest of the emulsion.Animal study. Kongkeaw et al., 2025 (Animals). PMID 41096476 ↗
- In a prospective observational cohort, higher measured serum monolaurin concentration was associated with lower odds of a subsequent viral respiratory illness outcome; this is an association in observed data and not evidence that supplementation caused the difference.Cohort study. Sola et al., 2025 (International Journal of Molecular Sciences). PMID 40141096 ↗
These are the studies our verdict leans on, chosen from the 2 we read for Monolaurin (Lauric Acid Derivative). The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.